DC
INMB icon

Diametric Capital’s INmune Bio INMB Stock Holding History

Diametric Capital’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,535
Closed -$129K – 358
2025
Q1 		$129K Sell
16,535
-20,164
-55% -$160K 0.15% 154
2024
Q4 		$171K Buy
36,699
+7,244
+25% +$37.8K 0.12% 248
2024
Q3 		$159K Buy
+29,455
New +$209K 0.08% 320
2021
Q1 		– Sell
-12,470
Closed -$215K – 176
2020
Q4 		$215K Buy
+12,470
New +$117K 0.17% 129

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Diametric Capital's INMB Position: Q2 2025 in Review

Diametric Capital sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 16,535 shares — an estimated $129K sold.

Diametric Capital first reported a position in INMB in Q4 2020 and held it in 4 quarters. The position peaked at $215K in Q4 2020. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

  • Diametric Capital reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
  • Diametric Capital sold 16,535 INmune Bio shares in Q2 2025, an estimated $129K.
  • Diametric Capital first reported a position in INmune Bio in Q4 2020 and held it in 4 quarters.
  • Diametric Capital's INmune Bio position peaked at $215K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on Diametric Capital's 13F filing for Q2 2025, filed 13 Aug 2025.